The Business Research Company’s Hematology
Drugs global market report, covers the year-on-year growth of the global Hematology Drugs market
historic and forecast growth. It also includes chapters on the Hematology
Drugs
market trends, geographical analysis, and competitive landscape.
Order
the report at:
The global hematology drugs market size is
expected to reach $50 billion by 2022, significantly growing at a CAGR of
around 6.5% during the forecast period.
Hematology
Drugs Market Trends
The
hematology drugs market consists of sales of hematology drugs and related
services by entities (organizations, sole traders and partnerships) that
produce hematology drugs to treat diseases such as genetic disorders, anemia,
other related diseases. This industry includes establishments that produce
blood products such as red blood cells, white blood cells, platelets, and fresh
frozen plasma. It also consists of establishments which produce of anemia and
other blood disorder drugs to treat anemia, hemophilia and blood clots.
The
increase in the number of drug approvals for hemophilia by the regulatory
bodies such as FDA in the US is an emerging trend in the market. For instance,
in June 2017, Novo Nordisk received FDA approval for its Rebinyn (Coagulation
Factor IX (Recombinant), GlycoPEGylated) drug that is used in the treatment of
haemophilia B. Over the last 17 years, there were no new drug approvals for the
treatment of haemophilia. However, there has been an uptake in the approval of
new drugs for the treatment of haemophilia. From 2014 to 2017, seven new drugs
have been approved by the FDA for treating haemophilia A and B. Increasing
number of new FDA approved drugs aids in management of hemophilics and improves
their Quality of Life (QoL).
The global Hematology Drugs market is primarily driven by increase
in unhealthy lifestyle leading to anemia and coagulation disorders, along with
increased longevity and the launch of pipeline drugs is set to drive the market
for haematology drugs.
Download
a sample of the report:
The global Hematology Drugs market report covers the
following regions under the geographical analysis section: Asia Pacific,
Western Europe, North America, Middle East, Africa, South America, and Eastern
Europe. Major countries under each of these regions are also covered under the
country analysis chapters.
With increase in the global old age population
who are more likely to suffer from blood disorder diseases such as anemia and
hemophilia, the global Hematology Drugs market is expected to increase in
potential and scope. TBRC’s report also covers the Hematology Drugs drivers and
restraints in the market.
The global Hematology Drugs market’s segment shares in
each geographic region are mentioned in the report, along with the historic and
forecast growth rates for each segment presented visually with supporting
reasons to justify the growth rates.
The top companies included in the global Hematology
Drugs market report are Novo Nordisk A/S, Shire Plc, Bayer AG, Daiichi Sankyo
Company, Biogen Inc.
About The Business Research Company:
The Business Research Company is
a Business Intelligence Company which excels in company, market and consumer
research. It has offices in the UK, the US and India and a network of trained
researchers in 15 countries globally.
Contact Information
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 8897263534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow us on LinkedIn: https://in.linkedin.com/company/the-business-research-company
No comments:
Post a Comment